| Clone | UCHT1 |
| Isotype | IgG1 |
| Product Type | Primary Antibodies |
| Units | 2ml (100 Tests) |
| Host | Mouse |
| Species reactivity | Human |
| Application | Flow CytometryImmunofluoresenceIndirect Immunofluorescence |
BackgroundUCHT1 is directed against human CD3 – the multichain complex associated with the T-cell receptor. Precursor T-cells are surface CD3 negative but positive for cytoplasmic CD3. All mature T-cells are both cytoplasmic and surface CD3 positive. The UCHT1 antibody permits the identification and enumeration of normal and leukemic human blood and bone marrow cells using flow cytometry. Results must be put within the context of other diagnostic tests as well as the clinical history of the patient by a certified professional before final interpretation. Analyses performed with this antibody should be paralleled by positive and negative controls. If unexpected results are obtained which cannot be attributed to differences in laboratory procedures, please contact us.
Product2 ml of FITC-conjugated anti CD3 (clone UCHT1) in PBS pH 7.2, 1% BSA, and 0.05% NaN3, approximately 100 tests.
Product Form: FITC
Formulation: PBS pH 7.2, 1% BSA, 0.05% NaN3
Purification Method: Purified by Chromatography
SpecificityThe CD3 mAb (clone UCHT1) recognizes cytoplasmic CD3 epsilon in precursor T-cells and cytoplasmic and surface CD3 epsilon in mature T-lymphocytes. The sensitivity of UCHT1 mAb is determined by staining well-defined blood samples from representative donors with serial-fold mAb dilutions to obtain a titration curve that allows relating the mAb concentration to the percentage of stained cells and geometric MFI (mean fluorescence intensity).The sensitivity of UCHT1 mAb is determined by staining well-defined blood samples from representative donors with serial-fold mAb dilutions to obtain a titration curve that allows relating the mAb concentration to the percentage of stained cells and geometric MFI (mean fluorescence intensity).In practice, 50 µl of leukocytes containing 107 cells/ml are stained with 20 µl mAb of various dilutions to obtain a titration curve and to identify the saturation point and detection threshold. The final concentration of the product is then adjusted to be at least 3-fold above the detection threshold. In addition and to control lot-to-lot variation, the given lot is compared and adjusted to fluorescence standards with defined intensity
ApplicationsStaining Procedure for Surface CD3: Direct Immunofluorescence (Staining Procedure) Nordic-MUbio fluorochrome labeled antibodies are designed for use with either whole blood or isolated mononuclear cell (MNC) preparationsProposed staining procedure for whole blood in short: - For each sample add 50 µl of EDTA anti-coagulated blood to a 3-5 ml tube - Add 20 µl of the appropriate Nordic-MUbio monoclonal antibody conjugate - Incubate the tube for 15 minutes at 4°C or at room temperature in the dark - Add 100 µl Nordic-MUbio-LYSE (Cat.No. GAS-003) to each tube and incubate for 10 minutes at room temperature - Add 3-4 ml of destilled water and vortex, incubate for 5-10 minutes at room temperature- Centrifuge tube for 5 minutes at 300 g - Aspirate supernatant and resuspend pellet in 0.3 ml of sheath fluid - Analyze immediately or store samples at 2-8° C in the dark and analyze within 24 hoursFor “No-Wash” protocol please refer to www.nordicmubio.comProposed staining procedure for MNC in short: - Carefully add 20 µl antibody conjugate and 50-100 µl MNC to the bottom of a tube - Vortex at low speed for 1-2 seconds - Incubate for 15-30 minutes at 2-8°C or at room temperature - Centrifuge tubes for 5 minutes at 300 g - Remove supernatant, resuspend cells in 2-5 ml of phosphate buffered saline (PBS) and centrifuge cells again for 5 minutes at 300 g - Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1 % formaldehyde and store them at 2-8°C in the dark. - Analyze fixed cells within 24 hours Indirect Immunofluorescence (Staining Procedure) - Mix 20 µl Nordic-MUbio purified antibody with 50 µl whole blood or MNC suspension - Incubate for 15 minutes at 2-8°C - Wash cells with phosphate buffered saline (PBS)- Add to cell pellet 20 µl of affinity purified, fluorochrome labeled F(ab’)2 anti mouse Ig antibodies - Incubate for 15 minutes at 2-8°C - Wash cells with phosphate buffered saline (PBS) or proceed as described for direct stainingStaining Procedure for Cytoplasmatic CD3: Permeabilization and Staining Procedure - In combination with our Permeabilization Kit FIX&PERM® (Cat. No. GAS-002) intracellular CD3 can be easily stained in cell suspensions. - For each sample to be analyzed add 50 µl of whole blood, bone marrow or mononuclear cell suspension in a 5ml tube- Add 100 µl of Reagent A (Fixation Medium, stored and used at room temperature) - Incubate for 15 minutes at room temperature - Add 5ml phosphate buffered saline and centrifuge cells for 5 minutes at 300 g - Remove supernatant and add to cell pellet 100 µl Reagent B (Permeabilization Medium) and 20 µl of the CD3 monoclonal antibody conjugate - Vortex at low speed for 1-2 seconds - Incubate for 15 minutes at room temperature - Wash cells with phosphate buffered saline as described above - Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1.0 % formaldehyde and store them at 2- 8°C in the dark. - Analyze fixed cells within 24 hours.
StorageNordic-MUbio monoclonal antibody reagents contain optimal concentrations of affinity-purified antibody. For stability reasons this monoclonal antibody solution contains sodium azide. These reagents should be stored at 2-8°C (DO NOT FREEZE!) and protected from prolonged exposure to light. If a slight precipitation occurs upon storage, this should be removed by centrifugation. It will not affect the performance or the concentration of the product. Stability of the reagent: Please refer to the expiry date printed onto the vial. The use of the reagent after the expiration date is not recommended.
CautionThis product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
References1. Paietta, E. (2003) Best Pract Res Clin Haematol 16, 671-83. 2. Braylan, R. C., Orfao, A., Borowitz, M. J. & Davis, B. H. (2001) Cytometry 46, 23-7. 3. Lanza, F., Latorraca, A., Moretti, S., Castagnari, B., Ferrari, L. & Castoldi, G. (1997) Cytometry 30, 134-44. 4. Groeneveld, K., te Marvelde, J. G., van den Beemd, M. W., Hooijkaas, H. & van Dongen, J. J. (1996) Leukemia 10, 1383-9. 5. Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21. 6. Janossy, G., Coustan-Smith, E. & Campana, D. (1989) Leukemia 3, 170-81. 7. Clevers, H., Alarcon, B., Wileman, T. & Terhorst, C. (1988) Annu Rev Immunol 6, 629-62.8. Wering, E. R. & Terhorst, C. (1988) Blood 71, 603-12. 9. Rani, S., De Oliveira, M. S. & Catovsky, D. (1988) Hematol Pathol 2, 73-8. 10. van der Schoot, C. E., von dem Borne, A. E. & Tetteroo, P. A. (1987) Acta Haematol 78 Suppl 1, 32-40. 11. van Dongen, J. J., Krissansen, G. W., Wolvers-Tettero, I. L., Comans-Bitter, W. M., Adriaansen, H. J., Hooijkaas, H., van Campana, D., Thompson, J. S., Amlot, P., Brown, S. & Janossy, G. (1987) J Immunol 138, 648-55. 12. Burns, G. F., Boyd, A. W. & Beverley, P. C. (1982) J Immunol 129, 1451-713. Beverley, P. C., Linch, D. & Callard, R. E. (1981) Haematol Blood Transfus 26, 309-13.
WarrantyThe products sold hereunder are warranted only to conform to the quantity and contents stated on the label at the time of delivery to the customer. There are no warranties, expressed or implied, that extend beyond the description on the label of the product. Exalpha`s sole liability is limited to either replacement of the products or refund of the purchase price. Exalpha is not liable for property damage, personal injury, or economic loss caused by the product.
CE MarkCE
Safety Datasheet(s) for this product:EA_Sodium Azide/wp-content/uploads/SDS/Antibody SDS with Sodium AzideV2.pdf
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
ELISA双抗体夹心法(enzyme linked immunosorbent assay——sandwich technique)的原理是将特异性抗体结合到固相载体上形成固相抗体,然后和待检血清中的相应抗原结合形成免疫复合物,洗涤后再加酶标记抗体,与免疫复合物中抗原结合形成酶标抗体-抗原-固相抗体复合物,加底物显色,判断抗原含量。
生物帮有相关介绍。编码RNA http://doc.bio1000.com/show-3399.html
请大家帮帮忙,第一步加完抗原后必须封闭吗
表面抗体是双抗原夹心法
E抗体和核心抗体是竞争抑制法或间接法
在这种测定方法中有3种必要的试剂:①固相的抗原或抗体(免疫吸附剂) ②酶标记的抗原或抗体(标记物)③酶作用的底物(显色剂)
测量时,抗原(抗体)先结合在固相载体上,但仍保留其免疫活性,然后加一种抗体(抗原)与酶结合成的偶联物(标记物),此偶联物仍保留其原免疫活性与酶活性,当偶联物与固相载体上的抗原(抗体)反应结合后,再加上酶的相应底物,即起催化水解或氧化还原反应而呈颜色。
其所生成的颜色深浅与欲测的抗原(抗体)含量成正比。 这种有色产物可用肉眼、光学显微镜、电子显微镜观察,也可以用分光光度计(酶标仪)加以测定。其方法简单,方便迅速,特异性强。向左转|向右转
2.加大辣根过氧化物酶标记的链霉亲和素;
1.标准曲线的标准品是否一定要梯度稀释,为什么?我试过非梯度稀释的,也可以达到线性R2=0.99.
2.我用了CurveExpert做标曲,自动搜索后发现有10种提供的方程,各种形式的,其中一个十分适合我的实验结果(LogisticModel),而其他的感觉又不适合,因为结果常常为负值。这又是为啥捏?
3.实验的酶标仪最大OD值可以测到4,如果我的测量结果在1.3,是否像其他人所说的>1了就不准确了。
4.利用夹心法进行定量分析是否一定要使用线性方程?
不好意思啊,一下问了这么多问题,最近做了一个月的ELISA,完全摸不清头脑啊。谢谢各位了

